Pulmonary Cell News 6.38 September 28, 2017 | |
| |
TOP STORYFor the first time, researchers have developed a way to coax pluripotent stem cells into a specific type of mature lung cell called “alveolar epithelial type II cells” and to correct a mutant gene whose dysfunction in these cells is known to cause respiratory distress in infants. [Press release from Boston University School of Medicine discussing online prepublication in Cell Stem Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)To model disease onset, progression, and chronicity, the authors exposed mice to pneumonia virus of mouse and cockroach extract in early-life and later-life, then challenged with rhinovirus (RV). Interventions included anti-IL-33 or dexamethasone at various stages of disease. Airway epithelial cells were obtained from asthmatic and healthy patients, and treated with anti-IL-33 following RV infection. [J Allergy Clin Immunol] Abstract Researchers found that Liuweibuqi capsules reduced the damage in the lung tissues and the loss of lung function in the COPD rats. The levels of interleukin (IL)-1β, interferon γ, IL-6, tumor necrosis factor-α and transforming growth factor-β1 were higher, whereas IL-10 was lower in the model control and cigarette smoke extract combined with lipopolysaccharide groups than in the normal group. [Cell Physiol Biochem] Full Article LUNG CANCEROverexpression of lncRNA IGFBP4–1 Reprograms Energy Metabolism to Promote Lung Cancer Progression The authors conducted bioinformatics analysis and found insulin-like growth factor binding protein 4–1 (IGFBP4–1) as a new candidate lncRNA located in the upstream region of IGFBP4 gene. [Mol Cancer] Full Article MicroRNA-196b Inhibits Cell Growth and Metastasis of Lung Cancer Cells by Targeting Runx2 Scientists explored the role of miR-196b in lung cancer and its possible underlying mechanism. Human lung cancer cell line A549 was transfected with miR-196b mimic, miR-196b inhibitor and corresponding controls. [Cell Physiol Biochem] Full Article Interleukin-6 Blockade Attenuates Lung Cancer Tissue Construction Integrated by Cancer Stem Cells The authors successfully generated lung cancer stem cell (CSC)-like cells by introducing a small set of transcription factors into a lung cancer cell line. In addition to properties that are conventionally referred to as CSC properties, the lung induced CSCs exhibited the ability to form lung cancer-like tissues in vitro with vascular cells and mesenchymal stem cells, which showed structures and immunohistological patterns that were similar to human lung cancer tissues. [Sci Rep] Full Article Researchers identified a high level of expression of miR-155 in a human lung adenocarcinoma cell line that is highly resistant to arsenic trioxide. They showed that the high level of miR-155 was associated with increased levels of cell survival, colony formation, cell migration and decreased cellular apoptosis, and this was mediated by high levels of Nrf2, NAD(P)H quinone oxidoreductase 1, heme oxygenase-1 and a high ratio of Bcl-2/Bax. [Sci Rep] Full Article MiR-367 Stimulates Wnt Cascade Activation through Degrading FBXW7 in NSCLC Stem Cells Investigators explored the functions of the endogenous miR-367 in stem-like cells isolated from non-small cell lung carcinoma (NSCLC) cell lines. In HEK-293 cells, they identified FBXW7 as the direct downstream gene of miR-367, which consequently released the LIN-28 dependent inhibition of suppressive Let-7. [Cell Cycle] Abstract Scientists investigated whether 3,6-dimethoxy-1,4,5,8-phenanthrenetetraone (NCKU-21) has potential activity to induce effective toxicological effects in different ethnic non-small cell lung cancer cell lines, A549 and CL1-5 cells, and examined its anticancer mechanisms. [PLoS One] Full Article | |
| |
REVIEWSStrategies for the Etiological Therapy of Cystic Fibrosis Etiological therapies aim at repairing the underlying cause of CF, which is the functional defect of the cystic fibrosis transmembrane conductance regulator (CFTR) protein owing to mutations in the CFTR gene. Scientists analyze distinctive advantages and drawbacks of these strategies in terms of their scientific and clinical dimensions, and propose a global strategy for CF research and development based on a reconciliatory approach. [Cell Death Differ] Full Article Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSAbbVie and Bristol-Myers Squibb Company announced a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo in c-Met overexpressing non-small cell lung cancer. [AbbVie] Press Release Prometic Life Sciences Inc. announced that its oral anti-fibrotic lead drug candidate, PBI-4050, has received FDA Investigational New Drug (IND) approval to commence its pivotal Phase II/III clinical trial in patients suffering from idiopathic pulmonary fibrosis. [Prometic Life Sciences Inc.] Press Release Asterias Biotherapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency and the NHS Research Ethics Committee have provided the necessary approvals to initiate the first-in-human clinical trial of AST-VAC2 in the United Kingdom (UK). The trial, which is being sponsored and managed by Cancer Research UK, will examine the safety, tolerability, immunogenicity and activity of AST-VAC2 in non-small cell lung cancer patients and is expected to be initiated later this year. [Asterias Biotherapeutics, Inc.] Press Release | |
| |
POLICY NEWSCanada Names New Chief Science Adviser Mona Nemer, a cardiology researcher and vice-president of research at the University of Ottawa, has been named Canada’s new Chief Science Adviser by Prime Minister Justin Trudeau. [ScienceInsider] Editorial Senate Panel Blocks NIH from Revising Translational Research Awards A congressional spending panel has backed scientists running a $516 million network of bench-to-bedside research centers in their fight with the National Institutes of Health (NIH) in Bethesda, Maryland, over how it manages the network. It’s the latest step in a long-running tug-of-war over the direction of the Clinical and Translational Science Awards program. [ScienceInsider] Editorial What’s the Evidence? Congress Struggles to Understand New Report on Evidence-Based Policy Every member of Congress probably wants to use evidence to make better policy. But a hearing this week suggests it might be a mistake to press lawmakers for details, or ask what they mean by evidence. [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Precision Medicine in Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Professor of Research – Lung Immunology (Tulane Medical School) NEW PhD Position – Molecular Pharmacology (University of Groningen) NEW Faculty Position – Lung Injury and Repair (The University of Texas Health Science Center) Research Scientist – Lung Cancer Models (The Francis Crick Institute) Postdoctoral Fellow – Non-Small-Cell-Lung-Cancer (University of Gothenburg) Postdoctoral Fellow – Pulmonary Fibrosis (University of Michigan) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|